Mabpharm Limited (HKG:2181)
Hong Kong · Delayed Price · Currency is HKD 0.3900
-0.0300 (-7.14%)
Sep 18, 2026, 4:08 PM HKT
Mabpharm Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 769.85 | 646.1 | 258.23 | 87.16 | 55.92 | 82.88 |
| 769.85 | 646.1 | 258.23 | 87.16 | 55.92 | 82.88 | |
Revenue Growth | 81.60% | 150.20% | 196.27% | 55.87% | -32.53% | - |
Cost of Revenue | 75.89 | 72.44 | 38.83 | 11.92 | 15.38 | 16.78 |
Gross Profit | 693.96 | 573.65 | 219.39 | 75.24 | 40.54 | 66.11 |
Selling, General & Admin | 596.13 | 511.19 | 261.98 | 153.58 | 118.77 | 100.06 |
Research & Development | 59.66 | 57.53 | 75.21 | 123.21 | 147.91 | 263.57 |
Operating Expenses | 658.09 | 568.85 | 339.07 | 277.22 | 266.79 | 363.63 |
Operating Income | 35.87 | 4.8 | -119.67 | -201.98 | -226.25 | -297.52 |
Interest Expense | -10.71 | -10.81 | -10.55 | -9.58 | -7.19 | -2.4 |
Interest & Investment Income | 0.41 | 0.43 | 0.51 | 0.15 | 0.38 | 1.95 |
Currency Exchange Gain (Loss) | 3.8 | 1.41 | -1.2 | -1.37 | -4 | -6.59 |
Other Non Operating Income (Expenses) | 3.14 | 8.26 | 2.69 | 3.08 | 25.92 | 12.89 |
EBT Excluding Unusual Items | 32.5 | 4.09 | -128.22 | -209.7 | -211.14 | -291.67 |
Gain (Loss) on Sale of Investments | 0.1 | 0.07 | 0.12 | 0.34 | 0.04 | - |
Gain (Loss) on Sale of Assets | - | - | - | - | 0.03 | -0.07 |
Other Unusual Items | 0.03 | - | 0.16 | - | 0.24 | - |
Pretax Income | 32.62 | 4.16 | -127.95 | -209.36 | -210.82 | -291.74 |
Income Tax Expense | -52.97 | -52.97 | - | - | - | - |
Earnings From Continuing Operations | 85.6 | 57.13 | -127.95 | -209.36 | -210.82 | -291.74 |
Net Income | 85.6 | 57.13 | -127.95 | -209.36 | -210.82 | -291.74 |
Net Income to Common | 85.6 | 57.13 | -127.95 | -209.36 | -210.82 | -291.74 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 4,124 | 4,124 | 4,124 | 4,124 | 4,124 | 4,124 |
Shares Outstanding (Diluted) | 4,124 | 4,124 | 4,124 | 4,124 | 4,124 | 4,124 |
Shares Change | - | - | - | - | - | - |
EPS (Basic) | 0.02 | 0.01 | -0.03 | -0.05 | -0.05 | -0.07 |
EPS (Diluted) | 0.02 | 0.01 | -0.03 | -0.05 | -0.05 | -0.07 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 83.71 | 39.7 | -30.24 | 38.35 | -182.01 | -348.14 |
Free Cash Flow Per Share | 0.02 | 0.01 | -0.01 | 0.01 | -0.04 | -0.08 |
Gross Margin | 90.14% | 88.79% | 84.96% | 86.32% | 72.50% | 79.76% |
Operating Margin | 4.66% | 0.74% | -46.34% | -231.74% | -404.61% | -358.97% |
Profit Margin | 11.12% | 8.84% | -49.55% | -240.19% | -377.01% | -352.00% |
Free Cash Flow Margin | 10.87% | 6.14% | -11.71% | 44.00% | -325.50% | -420.04% |
EBITDA | 90.12 | 59.28 | -65.94 | -150.13 | -183.68 | -262.78 |
EBITDA Margin | 11.71% | 9.18% | -25.54% | -172.24% | - | - |
D&A For EBITDA | 54.25 | 54.47 | 53.73 | 51.86 | 42.57 | 34.74 |
EBIT | 35.87 | 4.8 | -119.67 | -201.98 | -226.25 | -297.52 |
EBIT Margin | 4.66% | 0.74% | -46.34% | -231.74% | - | - |